Skip to content

<img width="302" height="74" src="https://therivabio.com/wp-content/uploads/2023/08/TherivaTM-logo-final-White.svg" class="custom-logo" alt="Theriva™ Biologics" decoding="async" />

ABOUT US
OUR SCIENCE
OUR PIPELINE
RESOURCES
CAREERS
INVESTORS
CONTACT

ABOUT US
OUR SCIENCE
OUR PIPELINE
RESOURCES
CAREERS
INVESTORS
CONTACT

<img width="302" height="74" src="https://therivabio.com/wp-content/uploads/2023/08/TherivaTM-logo-final-White.svg" class="custom-logo" alt="Theriva™ Biologics" decoding="async" />

ABOUT US
OUR SCIENCE
OUR PIPELINE
RESOURCES
CAREERS
INVESTORS
CONTACT

News

Choose Language
Sort by Year
Search

April 8, 2024

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

March 25, 2024

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

March 19, 2024

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

March 11, 2024

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

February 7, 2024

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

January 16, 2024

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

November 13, 2023

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

November 6, 2023

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

November 2, 2023

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

November 2, 2023

Theriva™ Biologics to Participate in the BIO-Europe Conference

Investor Relations Contact

Contact: Chris Calabrese

LifeSci Advisors, LLC

Tel: +917-680-5608

ccalabrese@lifesciadvisors.com

Email Alerts Sign-Up

[lsc-email]

9605 Medical Center Dr.
Suite 270
Rockville, MD 20850
info@therivabio.com

Theriva™

About Us
Our Science
Our Pipeline
Resources
Careers
Contact

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Privacy Policy
Disclaimer

© 2024 Theriva™ Biologics. All rights reserved.